{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:15:39Z","timestamp":1788401739229,"version":"build-2803163510"},"reference-count":44,"publisher":"American Chemical Society (ACS)","issue":"12","license":[{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccbyncnd_termsofuse.html"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Institute for Molecules and Materials, Radboud University","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autoreactive B cells are thought to play a pivotal role in many autoimmune diseases. Rheumatoid arthritis (RA) is an autoimmune disease affecting \u223c1% of the Western population and is hallmarked by the presence of anticitrullinated proteins antibodies (ACPA) produced by autoreactive B cells. We intend to develop a method to target and selectively eliminate these autoreactive B cells using a sequential antigen prodrug targeting strategy. As ACPA-expressing B cells are thought to play essential roles in RA-disease pathogenesis, we used this B cell response as a prototype to analyze the feasibility to generate a construct consisting of a biologically silenced, that is, blocked, antigen connected to a cytotoxic prodrug. Blocking of the antigen is considered relevant as it is anticipated that circulating autoantibodies will otherwise clear the antigen-prodrug before it can reach the target cell. The antigen-prodrug can only bind to the autoantigen-specific B cell receptor (BCR) upon enzymatic removal of the blocking group in close proximity of the B cell surface. BCR binding ultimately induces antigen-specific cytotoxicity after internalization of the antigen. We have synthesized a cyclic citrullinated peptide (CCP) antigen suitable for BCR binding and demonstrated that binding by ACPA was impaired upon introduction of a carboxy-p-nitrobenzyl (CNBz) blocking group at the side chain of the citrulline residue. Enzymatic removal of the CNBz moiety by nitroreductase fully restored citrulline-specific recognition by both ACPA and ACPA-expressing B cells and showed targeted cell death of CCP-recognizing B cells only. These results mark an important step toward antigen-specific B cell targeting in general and more specifically in RA, as successful blocking and activation of citrullinated antigens forms the basis for subsequent use of such construct as a prodrug in the context of autoimmune diseases.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.8b00741","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T13:34:31Z","timestamp":1538746471000},"page":"5565-5573","source":"Crossref","is-referenced-by-count":13,"title":["Sequential Prodrug Strategy To Target and Eliminate\nACPA-Selective Autoreactive B Cells"],"prefix":"10.1021","volume":"15","author":[{"given":"Lianne P. W. M.","family":"Lelieveldt","sequence":"first","affiliation":[{"name":"Radboud University , ,","place":["Nijmegen, The Netherlands, 6525 AJ"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendy","family":"Kristyanto","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center , , ,","place":["Leiden, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ger J. M.","family":"Pruijn","sequence":"additional","affiliation":[{"name":"Radboud University , ,","place":["Nijmegen, The Netherlands, 6525 AJ"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Ulrich","family":"Scherer","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center , , ,","place":["Leiden, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene\u0301 E. M.","family":"Toes","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center , , ,","place":["Leiden, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9498-2620","authenticated-orcid":true,"given":"Kimberly M.","family":"Bonger","sequence":"additional","affiliation":[{"name":"Radboud University , ,","place":["Nijmegen, The Netherlands, 6525 AJ"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2018,10,5]]},"reference":[{"issue":"5","key":"2026090221470875000_cit1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/ar2780","article-title":"B cells\nin autoimmunity","volume":"11","author":"Do\u0308rner","year":"2009","journal-title":"Arthritis Research & Therapy"},{"issue":"9746","key":"2026090221470875000_cit2","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid\narthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"2026090221470875000_cit3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/ar1184","article-title":"Citrullinated\nproteins: sparks that may ignite the\nfire in rheumatoid arthritis","volume":"6","author":"Vossenaar","year":"2004","journal-title":"Arthritis Research\nand Therapy"},{"issue":"6","key":"2026090221470875000_cit4","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.autrev.2015.01.013","article-title":"Citrullination and autoimmunity","volume":"14","author":"Valesini","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"2026090221470875000_cit5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1155\/2015\/728610","article-title":"The Role of Citrullinated Protein\nAntibodies in Predicting\nErosive Disease in Rheumatoid Arthritis: A Systematic Literature Review\nand Meta-Analysis","volume":"2015","author":"Jilani","year":"2015","journal-title":"Int. J. Rheumatol."},{"issue":"7","key":"2026090221470875000_cit6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrrheum.2011.76","article-title":"Anti-CCP antibodies:\nthe past, the present and the future","volume":"7","author":"van Venrooij","year":"2011","journal-title":"Nat. Rev.\nRheumatol."},{"issue":"25","key":"2026090221470875000_cit7","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of\nB-cell-targeted therapy with rituximab in patients with rheumatoid\narthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"2026090221470875000_cit8","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/ard.2010.148759","article-title":"Highest\nclinical effectiveness of rituximab in autoantibody-positive\npatients with rheumatoid arthritis and in those for whom no more than\none previous TNF antagonist has failed: pooled data from 10 European\nregistries","volume":"70","author":"Chatzidionysiou","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"2026090221470875000_cit9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jaip.2014.06.003","article-title":"Rituximab\nand Immune Deficiency: Case Series and Review of the Literature","volume":"2","author":"Kaplan","year":"2014","journal-title":"Journal of Allergy and Clinical Immunology: In Practice"},{"issue":"2","key":"2026090221470875000_cit10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1365-2567.2004.01875.x","article-title":"Selective\nkilling of B-cell hybridomas targeting proteinase 3, Wegener\u2019s\nautoantigen","volume":"112","author":"Reiners","year":"2004","journal-title":"Immunology"},{"issue":"7","key":"2026090221470875000_cit11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/intimm\/dxg076","article-title":"Specific depletion\nof autoreactive B lymphocytes by a recombinant fusion protein in vitro\nand in vivo","volume":"15","author":"Zocher","year":"2003","journal-title":"Int. Immunol."},{"issue":"1\u20132","key":"2026090221470875000_cit12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jneuroim.2008.01.001","article-title":"Depletion\nof autoreactive B-lymphocytes by a recombinant\nmyelin oligodendrocyte glycoprotein-based immunotoxin","volume":"195","author":"Nachreiner","year":"2008","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"2026090221470875000_cit13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12896-016-0249-x","article-title":"Novel fusion\nproteins for the antigen-specific staining\nand elimination of B cell receptor-positive cell populations demonstrated\nby a tetanus toxoid fragment C (TTC) model antigen","volume":"16","author":"Klose","year":"2016","journal-title":"BMC Biotechnol."},{"issue":"1","key":"2026090221470875000_cit14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1&lt;155::AID-ANR20&gt;3.0.CO;2-3","article-title":"The diagnostic\nproperties of rheumatoid arthritis antibodies recognizing a cyclic\ncitrullinated peptide","volume":"43","author":"Schellekens","year":"2000","journal-title":"Arthritis Rheum."},{"key":"2026090221470875000_cit15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1371\/journal.pone.0168542","article-title":"Physical Characteristics\nof a Citrullinated\nPro-Filaggrin Epitope Recognized by Anti-Citrullinated Protein Antibodies\nin Rheumatoid Arthritis Sera","volume":"11","author":"Trier","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"2026090221470875000_cit16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1172\/JCI1316","article-title":"Citrulline is an essential constituent\nof antigenic determinants recognized by rheumatoid arthritis-specific\nautoantibodies","volume":"101","author":"Schellekens","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"5","key":"2026090221470875000_cit17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.bcp.2009.10.008","article-title":"Discovery and evaluation\nof Escherichia coli nitroreductases that activate the anti-cancer\nprodrug CB1954","volume":"79","author":"Prosser","year":"2010","journal-title":"Biochem. Pharmacol."},{"issue":"13","key":"2026090221470875000_cit18","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1073\/pnas.85.13.4842","article-title":"Anti-tumor\neffects of antibody-alkaline phosphatase conjugates in combination\nwith etoposide phosphate","volume":"85","author":"Senter","year":"1988","journal-title":"Proc. Natl. Acad.\nSci. U. S. A."},{"key":"2026090221470875000_cit19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.addr.2017.06.013","article-title":"Prodrugs in medicinal chemistry and\nenzyme prodrug therapies","volume":"118","author":"Walther","year":"2017","journal-title":"Adv. Drug Delivery\nRev."},{"key":"2026090221470875000_cit20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2017.09.009","article-title":"Antibody Directed Enzyme Prodrug Therapy (ADEPT): Trials\nand tribulations","volume":"118","author":"Sharma","year":"2017","journal-title":"Adv. Drug Delivery Rev."},{"issue":"2","key":"2026090221470875000_cit21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1042\/BJ20150650","article-title":"Nitroreductase gene-directed enzyme\nprodrug therapy:\ninsights and advances toward clinical utility","volume":"471","author":"Williams","year":"2015","journal-title":"Biochem. J."},{"issue":"21","key":"2026090221470875000_cit22","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1021\/jm00047a002","article-title":"Self-immolative\nprodrugs: candidates for antibody-directed enzyme prodrug therapy\nin conjunction with a nitroreductase enzyme","volume":"37","author":"Mauger","year":"1994","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026090221470875000_cit23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0163-7258(99)00018-2","article-title":"Receptor-mediated\nand enzyme-dependent targeting of\ncytotoxic anticancer drugs","volume":"83","author":"Dubowchik","year":"1999","journal-title":"Pharmacol. Ther."},{"issue":"11","key":"2026090221470875000_cit24","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC Linker\nChemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm. Res."},{"issue":"23","key":"2026090221470875000_cit25","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1016\/0960-894X(95)00495-F","article-title":"A novel\nenediyne prodrug for antibody-directed\nenzyme prodrug therapy (ADEPT) using E. coli B nitroreductase","volume":"5","author":"Hay","year":"1995","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"19","key":"2026090221470875000_cit26","doi-asserted-by":"publisher","first-page":"6522","DOI":"10.1021\/jacs.7b01431","article-title":"Genetically Encoded\nPhotoaffinity Histone Marks","volume":"139","author":"Xie","year":"2017","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"2026090221470875000_cit27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nm.2071","article-title":"Generation of stable monoclonal antibody-producing\nB cell receptor-positive human memory B cells by genetic programming","volume":"16","author":"Kwakkenbos","year":"2010","journal-title":"Nat. Med."},{"key":"2026090221470875000_cit28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/annrheumdis-2018-213418","article-title":"Mast cells in early rheumatoid arthritis\nassociate with disease severity and support B cell autoantibody production","author":"Rivellese","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"2026090221470875000_cit29","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1136\/annrheumdis-2014-207182","article-title":"Identification\nand characterisation of citrullinated\nantigen-specific B cells in peripheral blood of patients with rheumatoid\narthritis","volume":"75","author":"Kerkman","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"2026090221470875000_cit30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/imr.12395","article-title":"Stable long-term cultures\nof self-renewing B cells and their applications","volume":"270","author":"Kwakkenbos","year":"2016","journal-title":"Immunological reviews"},{"issue":"1","key":"2026090221470875000_cit31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/ard.2010.131102","article-title":"Anti-cyclic\ncitrullinated peptide antibodies are a\ncollection of anti-citrullinated protein antibodies and contain overlapping\nand non-overlapping reactivities","volume":"70","author":"Ioan-Facsinay","year":"2011","journal-title":"Ann. Rheum.\nDis."},{"issue":"7","key":"2026090221470875000_cit32","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/annrheumdis-2012-202893","article-title":"Circulating plasmablasts\/plasmacells\nas a source of anticitrullinated protein antibodies in patients with\nrheumatoid arthritis","volume":"72","author":"Kerkman","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"2026090221470875000_cit33","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic\nstem cell transplantation using a hematopoietic-cell-specific internalizing\nimmunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"2026090221470875000_cit34","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.4049\/jimmunol.177.5.2994","article-title":"High-affinity ligand\nprobes of CD22 overcome the threshold set by cis ligands to allow\nfor binding, endocytosis, and killing of B cells","volume":"177","author":"Collins","year":"2006","journal-title":"J. Immunol."},{"issue":"4","key":"2026090221470875000_cit35","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1046\/j.1365-2141.1996.d01-1730.x","article-title":"Saporin, a\nribosome-inactivating protein used to prepare immunotoxins, induces\ncell death via apoptosis","volume":"93","author":"Bergamaschi","year":"1996","journal-title":"Br. J. Haematol."},{"key":"2026090221470875000_cit36","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic\nstem cell transplantation using a hematopoietic-cell-specific internalizing\nimmunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"2026090221470875000_cit37","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3727\/096368914X679327","article-title":"Depletion of Alloreactive\nT-Cells by Anti-CD137-Saporin Immunotoxin","volume":"24","author":"Lee","year":"2015","journal-title":"Cell\ntransplantation"},{"issue":"2\u20133","key":"2026090221470875000_cit38","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s12026-014-8511-6","article-title":"Depletion\nof inflammatory dendritic cells with anti-CD209 conjugated to saporin\ntoxin","volume":"58","author":"Alonso","year":"2014","journal-title":"Immunol. Res."},{"issue":"1","key":"2026090221470875000_cit39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.leukres.2012.09.010","article-title":"Efficacy of a CD22-targeted\nantibody-saporin conjugate\nin a xenograft model of precursor-B cell acute lymphoblastic leukemia","volume":"37","author":"Kato","year":"2013","journal-title":"Leuk. Res."},{"issue":"12","key":"2026090221470875000_cit40","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/pros.21164","article-title":"Saporin\ntoxin-conjugated monoclonal antibody targeting prostate-specific membrane\nantigen has potent anticancer activity","volume":"70","author":"Kuroda","year":"2010","journal-title":"Prostate"},{"issue":"1","key":"2026090221470875000_cit41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/BOR.0000000000000356","article-title":"Anticitrullinated protein antibodies:\norigin and role in the pathogenesis of rheumatoid arthritis","volume":"29","author":"England","year":"2017","journal-title":"Curr. Opin. Rheumatol."},{"issue":"1","key":"2026090221470875000_cit42","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12929-016-0281-0","article-title":"Hypoxia and\nits implications in rheumatoid arthritis","volume":"23","author":"Quin\u0303onez-Flores","year":"2016","journal-title":"J.\nBiomed. Sci."},{"issue":"4","key":"2026090221470875000_cit43","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/0006-2952(92)90396-Z","article-title":"Metabolism of nad(p)h by blood components:\nRelevance\nto bioreductively activated prodrugs in a targeted enzyme therapy\nsystem","volume":"44","author":"Friedlos","year":"1992","journal-title":"Biochem. Pharmacol."},{"issue":"52","key":"2026090221470875000_cit44","doi-asserted-by":"publisher","first-page":"14112","DOI":"10.1002\/anie.201305969","article-title":"Click to\nRelease: Instantaneous Doxorubicin Elimination upon Tetrazine Ligation","volume":"52","author":"Versteegen","year":"2013","journal-title":"Angew. Chem., Int. Ed."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.8b00741","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/15\/12\/5565\/67091125\/acs.molpharmaceut.8b00741.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/15\/12\/5565\/67091125\/acs.molpharmaceut.8b00741.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:49:44Z","timestamp":1788400184000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/15\/12\/5565\/743173\/Sequential-Prodrug-Strategy-To-Target-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,5]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,10,5]]},"published-print":{"date-parts":[[2018,12,3]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00741","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,5]]}}}